- Home
- APH vs SNY Comparison
APH vs SNY Comparison
Compare APH & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APH
- SNY
- Stock Information
- Founded
- APH 1932
- SNY 1994
- Country
- APH United States
- SNY France
- Employees
- APH N/A
- SNY N/A
- Industry
- APH Electrical Products
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- APH Technology
- SNY Health Care
- Exchange
- APH Nasdaq
- SNY Nasdaq
- Market Cap
- APH 113.0B
- SNY 116.5B
- IPO Year
- APH 1991
- SNY N/A
- Fundamental
- Price
- APH $108.82
- SNY $50.61
- Analyst Decision
- APH Buy
- SNY Buy
- Analyst Count
- APH 10
- SNY 2
- Target Price
- APH $108.80
- SNY $65.00
- AVG Volume (30 Days)
- APH 7.7M
- SNY 2.8M
- Earning Date
- APH 07-23-2025
- SNY 07-31-2025
- Dividend Yield
- APH 0.61%
- SNY 3.16%
- EPS Growth
- APH 50.29
- SNY 118.56
- EPS
- APH 2.51
- SNY 8.65
- Revenue
- APH $18,818,000,000.00
- SNY $53,714,621,258.00
- Revenue This Year
- APH $41.81
- SNY $2.85
- Revenue Next Year
- APH $9.80
- SNY $6.65
- P/E Ratio
- APH $43.36
- SNY $5.86
- Revenue Growth
- APH 40.51
- SNY 15.65
- 52 Week Low
- APH $56.45
- SNY $44.73
- 52 Week High
- APH $112.35
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- APH 56.79
- SNY 61.29
- Support Level
- APH $104.71
- SNY $48.23
- Resistance Level
- APH $112.02
- SNY $51.24
- Average True Range (ATR)
- APH 2.60
- SNY 0.70
- MACD
- APH -0.47
- SNY 0.37
- Stochastic Oscillator
- APH 53.80
- SNY 87.65
About APH Amphenol Corporation
Amphenol is a global supplier of connectors, sensors, and interconnect systems. Amphenol holds the second-largest connector market share globally and sells into the end markets of automotive, broadband, commercial air, industrial, IT and data communications, military, mobile devices, and mobile networks. Amphenol is diversified geographically, with operations in 40 countries.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.